Hereby, centering on CCL2 in PDAC, we demonstrated that CCL2 manifests as a pro‐tumoral factor that modulates M‐MDSC recruitment and functionality and rears a tumor‐tolerant immune microenvironment. The gene discussed is CCL2; the disease is neoplasm.